Patients with myelodysplastic syndromes (MDS) harbouring a clonal deletion of the long arm of chromosome 5 [del(5q)] display characteristic cytomorphologic features. 1, 2 Flow cytometry (FCM) is currently considered complementary to the microscopic evaluation of bone marrow (BM) smears and karyotyping and has been referred as a supplementary method in otherwise non-informative cases.
3 FCM-scoring-systems (FCSS and Ogata-score) 4, 5 
have been developed evolving from an analysis of progenitors and myelomonocytic cells. The European LeukemiaNet (ELN)-iMDS-FCM
working group has successfully made efforts in order to foster standardization arguing for the inclusion of FCM in the diagnostic work up of patients with a suspicion of MDS. 3, 6 It is however still unknown whether cytogenetic subgroups are associated with a distinct FCM profile thus allowing classification and disease monitoring. The aim of this twocenter-study was to compare the immunophenotype of different hematopoietic cell lineages in MDS patients with and without del(5q).
We investigated 156 untreated MDS patients within a training cohort, 38 patients showed a del(5q), including 26 patients with del(5q) as a single abnormality or with one additional aberration. An additional "validation cohort" consisted of 64 MDS [22 with del(5q), 12 showing del(5q) as single abnormality or with one additional aberration]. A standardized lyse-stain-wash procedure, using 8-color or 4-color staining (Dresden or Amsterdam laboratory, respectively), was performed. This allowed for a comprehensive FCM analysis according to FCSS and Ogata-score. 4, 5 We incorporated additional antigens, as CD10, its decrease in granulopoiesis described as loss of synchronicity in relation to other maturation antigens 7 , CD36/CD71 expression on granulopoiesis, feature associated with maturity within the progenitor cell compartment, was normal-tolow in each del(5q) patient. 4 Granulopoiesis presented with an abnormally low sideward scatter (SSC)-ratio in almost all del(5q) patients reflecting hypogranularity. Interestingly, this is known to be a rather uncommon cytomorphological feature in del(5q) MDS.
1,2
Notably, CD71 and CD10 expression were significantly more often normal compared to NK patients, pronouncing the maturity of granulopoiesis which is concordant with the low rate of dysgranulopoiesis evaluated cytomorphologically. considering the whole data set, the del(5q)-score was comparably low (mean: 11.5 vs.
11.0), with 25 patients comprising a score <10.0, never being present in del(5q) MDS.
Some of the mentioned variables are part of the Ogata-score 5 accentuating the importance of these features in MDS. Remarkably, the addition of two parameters (CD71 and gender) and the differential weighting further refined the Ogata-score and allowed for a clear separation of del(5q) and non-del(5q) MDS as well as non-clonal cytopenias and healthy BM (Table 2 ).
Finally, we tested in 18 MDS patients (71 measurements) whether the proposed 5-parameter-del(5q)-score could be used for monitoring response to lenalidomide and/or azacitidine. 13, 14 The del(5q)-specific-profile was lost (mean score=13.0) in all del (5q) patients achieving a complete cytogenetic response (cCR) after a lenalidomide-based therapy (n=13 measurements), including normal myPC and SSC-ratio (12/13 patients),
whereas in most measurements in MDS without cCR (45/58 patients) a characteristic high del(5q)-score (mean=16.5; Figure 1C -D) was present. A more complex aberrant karyotype as an expression of a higher grade of genetic instability might result in a different immunophenotype. However, a typical del(5q)-score reflected patients with a complex karyotype in a similar way as MDS with isolated del(5q). Namely, during all measurements in del(5q) MDS with complex karyotype, receiving azacitidine and not achieving a cCR, a typical high del(5q)-score was detectable. Additionally, only one patient without cCR but a non-typical del(5q)-score lower than the proposed threshold of 15.0 presented with a complex karyotype, both arguing for del(5q) as an early cytogenetic abnormality which drives the overall immunophenotype. In contrast, in del(5q) patients without a complete response to therapy but a non-typical low del(5q)-score this expression profile seems to be associated with the presence of a TP53 mutation. In 12/13 measurements with this non-typical low score (mean score=13.0; range=3.5-14.5) a TP53 mutation and/or a chromosome 17p deletion was present, whereas only 1/23 investigations in patients with wtTP53 had a non-typical low del(5q)-score (P=0.009). This observation hints at a possible link between TP53 mutations and concomitant alterations of the immunophenotypic profile. Thus, the del(5q)-score can be used as a reliable complementary tool for cytogenetic response in wtTP53 patients.
TP53 mutations in MDS with isolated del(5q) have been reported in up to 20% of lower risk MDS. 15 A mutational screening is recommended in patients with isolated del(5q) because of their potential resistance to lenalidomide and higher rate of AML evolution in TP53 mutated cases. From our data we hypothesize, that especially patients with isolated del(5q) but a non-typical low del(5q)-score might be suspicious of harboring a TP53 mutation and should subsequently be referred to mutational screening.
In summary, we demonstrate a strong association of a common cytogenetic (Table 1A) were included and a threshold of at least 8 was set. ‡ The final 5-parameter-del(5q)-score was established after logistic regression analysis including weighting and choosing of the most informative parameters. A threshold of at least 15.0 was applied.
§ Four patients have been excluded because of an incomplete data set. no., patient numbers; SD, standard deviation; BM, bone marrow. In 18 MDS patients with del(5q), 71 FCM investigations at diagnosis and during the disease course were performed. Within these patients were 10 MDS with del(5q) as a single abnormality and 1 patient with one additional aberration (trisomy 8) included, 7 receiving lenalidomide and 3 azacitidine, a combined treatment within the AZALE trial 1 ,
or an induction therapy with daunorubine plus cytarabine. The further 8 MDS patients
showed del(5q) as part of a complex aberrant karyotype and were treated with azacitidine alone (7 patients) or received a combined treatment within the AZALE trial.
This study was performed according to the principles of the Declaration of Helsinki and has received votes from the institutional review boards.
Flow cytometric immunophenotyping
FCM was performed on a FACSCanto II equipped with 3 lasers using FACS-DiVa software (BD Biosciences, San Jose, CA). Instrument set up including fluorescence amplification and compensation was fixed automatically applying FACS-DiVa compensation set up. Flow cytometer performance was checked using CS&T beads (BD Biosciences). In each sample 200000 events were registered. In the VU University
Medical Center, Amsterdam, measurements were performed on a FACSCalibur (BD Biosciences).
In both laboratories the applied Boolean gating strategy consisted of the exclusion of doublets and debris, followed by gating of the main populations according to their side scatter (SSC) and CD45 expression. For progenitors with subsequent separation in myeloid (myPC, CD34+CD19-) and lymphoid (lyPC, CD34+CD19+) progenitors CD34 expression and for monocytes CD33/CD36 expression and subsequent backgating to SSC/CD45 was added. Nucleated red cells (NRC) were characterized using CD45, CD235a, and CD71 expression.
We applied published thresholds for abnormal antigen expression as myPC >2.0%, lyPC <5.0%, SSC ratio -granulocytes vs. lymphocytes <6.0. 2, 3 All further cut-offs for abnormal expression, mean and 2 standard deviations (SD), have been determined after assessing healthy BM, myPC: CD7 >15.0%, CD45-MFI-ratio (lymphocytes vs. myPC) ≥7.0; granulopoiesis: CD10 ≤25.0%, CD36 >10.0%, CD71 >20.0%; monopoiesis: CD56 >20.0%; NRC: percentage >8.0, CD71 dim >10% of all CD71+ NRC).
The threshold for abnormal mean fluorescence intensity (MFI) was set at mean and 2 SD compared to normal BM (e.g. CD15 on granulocytes >5300 in the Dresden and >698 in the Amsterdam lab). 
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